Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 9.02% is 287% above its 5-year average of 2.33%, near the high end of its 5-year range (-4.37%–9.02%).
139.26% above its 12-month average of 3.77%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.22%.
RETURN ON ASSETS (ROA)
9.02%
RETURN ON ASSETS (ROA) AVG TTM
3.77%
RETURN ON ASSETS (ROA) AVG 3Y
2.45%
RETURN ON ASSETS (ROA) AVG 5Y
2.33%
RETURN ON ASSETS (ROA) AVG 10Y
10.66%
RETURN ON ASSETS (ROA) AVG 15Y
3.87%
RETURN ON ASSETS (ROA) AVG 20Y
0.63%
CURRENT VS TTM AVG
+139.26%
CURRENT VS 3Y AVG
+268.16%
CURRENT VS 5Y AVG
+287.12%
CURRENT VS 10Y AVG
-15.37%
CURRENT VS 15Y AVG
+132.98%
CURRENT VS 20Y AVG
+1326.42%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+127.98%
vs the sector median at left
Ligand Pharmaceuticals Incorporated
Market Cap
$5.92B
Return on Assets (ROA)
9.02%
TTM Avg
3.77%
3Y Avg
2.45%
5Y Avg
2.33%
Market Cap
$5.86B
Return on Assets (ROA)
-13.77%
TTM Avg
-40.95%
3Y Avg
-52.61%
5Y Avg
-44.58%
Market Cap
$5.87B
Return on Assets (ROA)
9.00%
TTM Avg
0.15%
3Y Avg
10.71%
5Y Avg
-11.86%
Market Cap
$5.81B
Return on Assets (ROA)
-31.62%
TTM Avg
-41.85%
3Y Avg
-50.05%
5Y Avg
-46.34%
Market Cap
$5.81B
Return on Assets (ROA)
-94.23%
TTM Avg
-58.97%
3Y Avg
-55.59%
5Y Avg
-44.06%
Market Cap
$6.20B
Return on Assets (ROA)
-46.96%
TTM Avg
-53.68%
3Y Avg
-52.55%
5Y Avg
-50.20%
Market Cap
$5.59B
Return on Assets (ROA)
-20.67%
TTM Avg
-16.00%
3Y Avg
-20.09%
5Y Avg
-20.45%
Market Cap
$5.51B
Return on Assets (ROA)
-0.50%
TTM Avg
-0.21%
3Y Avg
0.03%
5Y Avg
0.08%
Market Cap
$5.47B
Return on Assets (ROA)
-6.97%
TTM Avg
-6.55%
3Y Avg
-3.96%
5Y Avg
-3.96%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | $5.92B | 9.02% | 3.77% | 2.45% | 2.33% |
| GRAIL Inc. (GRAL)vs › | $5.86B | -13.77% | -40.95% | -52.61% | -44.58% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 9.00% | 0.15% | 10.71% | -11.86% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.81B | -31.62% | -41.85% | -50.05% | -46.34% |
| Kodiak Sciences Inc. (KOD)vs › | $5.81B | -94.23% | -58.97% | -55.59% | -44.06% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.20B | -46.96% | -53.68% | -52.55% | -50.20% |
| CG Oncology Inc. (CGON)vs › | $5.59B | -20.67% | -16.00% | -20.09% | -20.45% |
| RadNet, Inc. (RDNT)vs › | $5.51B | -0.50% | -0.21% | 0.03% | 0.08% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.47B | -6.97% | -6.55% | -3.96% | -3.96% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 4.17% | -0.69% | -1.80% | -0.78% |
ROA
9.0%
ROE
20.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 7.97% |
| 2024-12-31 | -0.43% |
| 2023-12-31 | 6.63% |
| 2022-12-31 | -4.37% |
| 2021-12-31 | 4.40% |
| 2020-12-31 | -0.22% |
| 2019-12-31 | 42.10% |
| 2018-12-31 | 11.37% |
| 2017-12-31 | 1.87% |
| 2016-12-31 | -0.27% |
| 2015-12-31 | 48.19% |
| 2014-12-31 | 4.66% |
| 2013-12-31 | 10.91% |
| 2012-12-31 | -0.51% |
| 2011-12-31 | 8.32% |
| 2010-12-31 | -16.56% |
| 2009-12-31 | -1.71% |
| 2008-12-31 | -57.23% |
| 2007-12-31 | 162.56% |
| 2006-12-31 | -9.74% |
| 2005-12-31 | -11.57% |
| 2004-12-31 | -13.58% |
| 2003-12-31 | -12.44% |
| 2002-12-31 | -12.05% |
| 2001-12-31 | -36.60% |
| 2000-12-31 | -63.81% |
| 1999-12-31 | -55.50% |
| 1998-12-31 | -75.58% |
| 1997-12-31 | -93.30% |
| 1996-12-31 | -36.53% |
